Ozempic, Rybelsus, and Wegovy may reduce the risk of major adverse cardiovascular events.

Cardiovascular Health and Weight Management

Promising preliminary results from the SELECT cardiovascular trial indicate Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity. This double-blinded trial has marked a significant advancement in the battle against major adverse cardiovascular events (MACEs) for individuals with overweight or obesity.

The SELECT trial set out to explore the effectiveness of subcutaneous once-weekly Semaglutide 2.4 mg as an adjunct to standard care in preventing MACEs over a span of up to five years. The trial enlisted 17,604 adults aged 45 years or older, who had both overweight or obesity and established cardiovascular disease (CVD), without any prior history of diabetes.

Semaglutide 2.4 mg has shown a 20% reduction in MACEs compared to placebo. The primary endpoint of the study encompassed cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. Astonishingly, all three components of this endpoint contributed to the superior MACE reduction demonstrated by Semaglutide 2.4 mg. A total of 1,270 first MACEs were documented throughout the trial.

But that's not all. Semaglutide 2.4 mg exhibited a safe and well-tolerated profile, consistent with previous trials of this medication. This is particularly significant since people living with obesity are at an elevated risk of cardiovascular disease.

However, it's crucial to remember that these studies are still in their preliminary stages. As with any medical decision, it's important to consult with your healthcare team before undergoing any treatment. Your doctors can provide personalized guidance based on your unique medical history and needs.

To shed light on the SELECT trial, it was a comprehensive study that spanned across 41 countries and involved over 800 investigator sites. The participants, all aged ≥45 years with a BMI ≥27 kg/m2, were meticulously selected to evaluate the efficacy of Semaglutide 2.4 mg in reducing the incidence of three-point MACEs. This included cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. Key secondary objectives of the trial encompassed mortality, cardiovascular risk factors, glucose metabolism, body weight, and renal function.

While more studies are required, these initial findings could be an exciting leap forward in the field of cardiovascular health and weight management.  Learn more about how Capital Cardiology’s Healthy Weight/Healthy Life Initiative can help you make a lasting change.

Written by John Bulmer, Public Information Officer, Capital Cardiology Associates